Next Article in Journal
Early Postoperative Low Expression of RAD50 in Rectal Cancer Patients Associates with Disease-Free Survival
Next Article in Special Issue
IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas
Previous Article in Journal / Special Issue
Targeting Autophagy in ALK-Associated Cancers
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessFeature PaperReview
Cancers 2017, 9(12), 164;

Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer

Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
Department of Medicine, University of California, San Francisco, CA 94115, USA
Author to whom correspondence should be addressed.
Received: 2 October 2017 / Revised: 14 November 2017 / Accepted: 28 November 2017 / Published: 30 November 2017
(This article belongs to the Special Issue Targeting ALK in Cancer)
Full-Text   |   PDF [2312 KB, uploaded 30 November 2017]   |  


Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified in lung cancer at 3–7% frequency, thus representing an important subset of genetic lesions that drive oncogenesis in this disease. Despite the availability of multiple FDA-approved small molecule inhibitors targeting ALK fusion proteins, drug resistance to ALK kinase inhibitors is a common problem in clinic. Thus, there is an unmet need to deepen the current understanding of genomic characteristics of ALK rearrangements and to develop novel therapeutic strategies that can overcome ALK inhibitor resistance. In this review, we present the genomic landscape of ALK fusions in the context of co-occurring mutations with other cancer-related genes, pointing to the central role of genetic epistasis (gene-gene interactions) in ALK-driven advanced-stage lung cancer. We discuss the possibility of targeting druggable domains within ALK fusion partners in addition to available strategies inhibiting the ALK kinase domain directly. Finally, we examine the potential of targeting ALK fusion-specific neoantigens in combination with other treatments, a strategy that could open a new avenue for the improved treatment of ALK positive lung cancer patients. View Full-Text
Keywords: anaplastic lymphoma kinase; ALK; dimerization inhibition; neoantigens; CAR-T; immunotherapy anaplastic lymphoma kinase; ALK; dimerization inhibition; neoantigens; CAR-T; immunotherapy

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Wu, W.; Haderk, F.; Bivona, T.G. Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. Cancers 2017, 9, 164.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top